HighTower Advisors
LRMR icon

HighTower Advisors’s Larimar Therapeutics LRMR Stock Holding History

HighTower Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Sell
37,698
-767
-2% -$3.04K ﹤0.01% 3643
2026
Q1 		$173K Buy
+38,465
New +$154K ﹤0.01% 3532
2019
Q3 		– Sell
-1,000
Closed -$14K – 2485
2019
Q2 		$14K Buy
+1,000
New +$26.6K ﹤0.01% 2275

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

HighTower Advisors's LRMR Position: Q2 2026 in Review

HighTower Advisors reduced its Larimar Therapeutics (LRMR) stake by 2% in Q2 2026, selling an estimated $3.04K and leaving 37,698 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #3643.

HighTower Advisors first reported a position in LRMR in Q2 2019 and has held it in 3 quarters since. The position peaked at $173K in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • HighTower Advisors held 37,698 shares of Larimar Therapeutics worth $115K as of Q2 2026.
  • HighTower Advisors sold 767 Larimar Therapeutics shares in Q2 2026, an estimated $3.04K.
  • Larimar Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3643 holding.
  • HighTower Advisors first reported a position in Larimar Therapeutics in Q2 2019 and has held it in 3 quarters since.
  • HighTower Advisors's Larimar Therapeutics position peaked at $173K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.